Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Tokyo Big Sight

Nov 13, 2016 9:30 AM - Nov 15, 2016 5:30 PM

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

13th DIA Japan Annual Meeting 2016

[V4-S5] Development of Disease-Modifying Drugs for Alzheimer’s Disease (AD); Utilizing the Use of Biomarkers

Session Chair(s)

Yoshiko  Komuro, PhD

Yoshiko Komuro, PhD

Inspection Director, Office of Non-Clinical and Clinical Compliance

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Developing a treatment for Alzheimer’s disease (AD) is an extremely critical issue as the world continues to age. Development of a disease-modifying drug that differs from the existing symptomatic drugs, by slowing or stopping disease progression is highly desired. For more than ten years, such disease-modifying drugs have been actively developed, but none have been approved. Difficulties in selecting appropriate patients and evaluating efficacy are considered the major reasons for this lack of approval. Recent studies utilized biomarkers that reflect the pathophysiological changes of AD to overcome some of these issues. This session will discuss the issues surrounding the development of disease-modifying drugs for AD, and points to consider while utilizing these biomarkers.

Speaker(s)

Haruhiko  Akiyama, MD, PhD

Treatments of Alzheimer’s Disease: Current Therapy and Future Direction

Haruhiko Akiyama, MD, PhD

Yokohama Brain and Spine Center, Japan

Director, Department of Clinical Research

Yoichi  Inoue, JD, MD

Biomarkers of Alzheimer's Disease - Based on Imaging Technology

Yoichi Inoue, JD, MD

GE Healthcare Japan, Japan

Medical Affair, Japan

Ichiro  Arano, PhD

Opportunities and Challenges of Biomarker in Development of Disease-Modifying Drugs for AD

Ichiro Arano, PhD

MSD K.K., Japan

Director, Primary Care, Clinical Operation

Takaaki  Suzuki, PhD

Takaaki Suzuki, PhD

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Reviewer, Office of New Drug II

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.